Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis

Journal of Dermatology

Volumn 44, Issue 10, 2017, Pages 1168-1171

  Miyagawa, Takuya ^a   Asano, Yoshihide ^a   de Mestier, Yuka ^a   Saigusa, Ryosuke ^a   Taniguchi, Takashi ^a   Yamashita, Takashi ^a   Nakamura, Kouki ^a   Hirabayashi, Megumi ^a   Miura, Shunsuke ^a   Ichimura, Yohei ^a   Takahashi, Takehiro ^a   Yoshizaki, Ayumi ^a   Miyagaki, Tomomitsu ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

alveolitis; H ficolin; innate immunity; interstitial lung disease; systemic sclerosis

Indexed keywords

FICOLIN; H FICOLIN; UNCLASSIFIED DRUG; FCN3 PROTEIN, HUMAN; GLYCOPROTEIN; LECTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INNATE IMMUNITY; INTERSTITIAL LUNG DISEASE; MALE; PATHOGENESIS; PREVALENCE; SYSTEMIC SCLEROSIS; BLOOD; COMPLEMENT ACTIVATION; DIAGNOSTIC IMAGING; IMMUNOLOGY; MIDDLE AGED; X-RAY COMPUTED TOMOGRAPHY;

AGED; COMPLEMENT ACTIVATION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNITY, INNATE; LECTINS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREVALENCE; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85018636733     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13877     Document Type: Article

References (15)

1. Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol 2015; 37: 489–500.
2. Runza VL, Schwaeble W, Mannel DN. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008; 213: 297–306.
3. Hummelshoj T, Fog LM, Madsen HO, Sim RB, Garred P. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol Immunol 2008; 45: 1623–32.
4. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
5. Kazerooni EA, Martinez FJ, Flint A et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977–83.
6. Bhattacharyya S, Tamaki Z, Wang W et al. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014; 6: 232ra50.
7. Akamata K, Asano Y, Aozasa N et al. Serum levels of mannose-binding lectin in systemic sclerosis: a possible contribution to the initiation of skin sclerosis in the diffuse cutaneous subtype. Eur J Dermatol 2014; 24: 123–125.
8. Salem GI, Abdulrahman AA. Evaluation of liver function tests in scleroderma patients. Rheumatol Int 2012; 32: 2371–5.
9. Mendoza FA, Piera-Velazquez S, Farber JL, Feghali-Bostwick C, Jimenez SA. Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 2016; 68: 210–7.
10. Laplante P, Raymond MA, Gagnon G et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005; 174: 5740–9.
11. Takahashi T, Asano Y, Nakamura K et al. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. Br J Dermatol 2016; 175: 1195–1203.
12. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43: 2550–62.
13. Morimoto K, Janssen WJ, Terada M. Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med 2012; 106: 1800–3.
14. Yoon YS, Kim SY, Kim MJ, Lim JH, Cho MS, Kang JL. PPARg activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. Mucosal Immunol 2015; 8: 1031–46.
15. Lee YJ, Moon C, Lee SH et al. Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction. Eur Respir J 2012; 40: 424–35.